Japanese Company Says New Oral COVID-19 Drug Ensitrelvir Achieves Primary Endpoint

Japanese Company Says New Oral COVID-19 Drug Ensitrelvir Achieves Primary Endpoint
A medical staffer shows tablets containing chloroquine, a drug that has shown signs of effectiveness against the virus that causes COVID-19, in Marseille, France, on Feb. 26, 2020. Gerard Julien/AFP/Getty Images
|Updated:
0:00

Japanese pharmaceutical company Shionogi’s new oral COVID-19 drug has achieved the primary endpoint in a clinical trial, the company announced in September.

From February to July, Shionogi conducted a clinical trial with 1,821 people to evaluate ensitrelvir fumaric acid (S-217622), the oral drug the company developed in February. The subjects were not at risk for other diseases and had been vaccinated.

Ellen Wan has worked for the Japanese edition of The Epoch Times since 2007.
Related Topics